ReviR Therapeutics Advances Dual-Target Small Molecule RNA-Targeting Pipeline for Huntington’s Disease, Files IPO Prospectus
ReviR Therapeutics
Innovative Drug Developer
Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
PharmaCircleLearned:Previously inNovember 20, 2025ReviR Therapeutics (ReviR Therapeutics, Inc., referred to as ReviR) announced that it has received a $4.6 million grant from CIRM (California Institute for Regenerative Medicine)., for the advancement of the company's independently developed "HTT-PMS1"Innovative Project Research. This project isSmall-molecule targeted RNA dual-target pipeline, indicated for Huntington's disease(Huntington's Disease, HD), has successfully obtained a lead compound that meets the standards.Achieve the First Core Milestone。
Mutant Huntingtin Protein (mHTT)AndMismatch Repair Enzyme PMS1As two key drivers in the pathogenesis of Huntington's disease,ReviR Therapeutics leverages its self-developed VoyageR AI platform and cutting-edge RNA-targeting technology to simultaneously target these two key factors. By using small molecules to induce RNA degradation, it reduces toxic protein levels and inhibits CAG repeat expansion, potentially blocking the long-term progression of the disease at its root.
